Semaglutide fatty acid sidechain — what worked for you?

carl_compliance said:

It helps to say which part of this you are uncertain about.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

Happy to go further on any of that.

NurseLeah_Nash said:

The dose-response is real but shallow at the top.

That reframing is the part I needed.

carl_compliance said:

It helps to say which part of this you are uncertain about.

I read this differently from carl_compliance, on substance rather than tone. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

One concrete data point for the thread. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Report rather than reply if it drifts again.